MedTrace Logo

Transepidermal Delivery of Triamcinolone Acetonide or Platelet Rich Plasma Using Either Fractional Carbon Dioxide Laser or Microneedling in Treatment of Alopecia Areata

NCT04147845 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-12-08

No results posted yet for this study

Summary

The aim of this study is to evaluate the use of fractional carbon dioxide laser versus microneedling in the transepidermal delivery of triamcinolone acetonide and platelet rich plasma in treatment of alopecia areata.

Conditions

Interventions

OTHER

Fractional Carbon Dioxide Laser

The ablative fractional CO2 laser is delivered to the patients' scalp. The fractional ablative method is applied immediately before the topcial medication. Laser treatment will be given to the affected area, and immediately after the treatment, the treatment solution will be dropped on the treated area and spread evenly

OTHER

Microneedling using dermapen

Microneedling is performed using Dermapen. This creates pin point bleeding or mild erythema which will be considered as the end point. The treatment solution will be applied on each lesion twice, before and after performing microneedling.

OTHER

Triamcinolone Acetonide

triamcinolone solution (10 mg/ml) will be dropped on the treated area and spread evenly

OTHER

Platelet-rich plasma

The applied PRP will be spread over the whole affected area

Sponsors & Collaborators

  • Alexandria University

    lead OTHER

Principal Investigators

  • Khaled El Mulla, MBBCh, MS, Ph.D · Professor of Dermatology,Venereology and Andrology, Faculty of Medicine, University of Alexandria

  • Eman Elmorsy, MBBCh, MS, Ph.D · Professor of Dermatology,Venereology and Andrology, Faculty of Medicine, University of Alexandria

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-30
Primary Completion
2020-11-27
Completion
2020-11-27

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04147845 on ClinicalTrials.gov